Beta-blockers in heart failure with preserved ejection fraction: a meta-analysis

Heart Failure Reviews

Volumn 20, Issue 2, 2015, Pages 193-201

  Bavishi, Chirag ^a   Chatterjee, Saurav ^a   Ather, Sameer ^b   Patel, Dipen ^a   Messerli, Franz H ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b University of Alabama at Birmingham   (United States)

Author keywords

Beta blockers; Heart failure with preserved ejection fraction; Meta analysis

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; NEBIVOLOL; PLACEBO; PROPRANOLOL;

ARTICLE; CAUSE OF DEATH; COHORT ANALYSIS; DRUG EFFICACY; DRUG USE; GEOGRAPHIC DISTRIBUTION; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HOSPITALIZATION; HUMAN; META ANALYSIS; MORBIDITY; MORTALITY; OBSERVATIONAL STUDY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; SURVIVAL; SYSTEMATIC REVIEW; TREATMENT RESPONSE; UNITED STATES; DRUG EFFECTS; HEART FAILURE; HEART STROKE VOLUME; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; HEART FAILURE; HOSPITALIZATION; HUMANS; MORTALITY; OBSERVATIONAL STUDIES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STROKE VOLUME; TREATMENT OUTCOME;

EID: 84928428048     PISSN: 13824147     EISSN: 15737322     Source Type: Journal    
DOI: 10.1007/s10741-014-9453-8     Document Type: Article

References (43)

1. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL (2013) 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American college of cardiology foundation/American heart association task force on practice guidelines. Circulation 128(16):1810–1852. doi:10.1161/CIR.0b013e31829e8807
2. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM (2006) Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 355(3):251–259. doi:10.1056/NEJMoa052256
3. Steinberg BA, Zhao X, Heidenreich PA, Peterson ED, Bhatt DL, Cannon CP, Hernandez AF, Fonarow GC. (2012) Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies, and outcomes. Circulation 126(1):65–75. doi:10.1161/CIRCULATIONAHA.111.080770
4. Ather S, Chan W, Bozkurt B, Aguilar D, Ramasubbu K, Zachariah AA, Wehrens XH, Deswal A (2012) Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction. J Am Coll Cardiol 59(11):998–1005. doi:10.1016/j.jacc.2011.11.040
5. Deswal A, Bozkurt B (2008) Treatment of patients with heart failure and preserved ejection fraction. Curr Treat Options Cardiovasc Med 10(6):516–528
6. Chatterjee S, Biondi-Zoccai G, Abbate A, D’Ascenzo F, Castagno D, Van Tassell B, Mukherjee D, Lichstein E (2013) Benefits of beta blockers in patients with heart failure and reduced ejection fraction: network meta-analysis. BMJ 346:f55. doi:10.1136/bmj.f55
7. Liu F, Chen Y, Feng X, Teng Z, Yuan Y, Bin J (2014) Effects of beta-blockers on heart failure with preserved ejection fraction: a meta-analysis. PLoS ONE 9(3):e90555. doi:10.1371/journal.pone.0090555
8. Aronow WS, Ahn C, Kronzon I (1997) Effect of propranolol versus no propranolol on total mortality plus nonfatal myocardial infarction in older patients with prior myocardial infarction, congestive heart failure, and left ventricular ejection fraction > or = 40% treated with diuretics plus angiotensin-converting enzyme inhibitors. Am J Cardiol 80(2):207–209
9. Fonarow GC, Stough WG, Abraham WT, Albert NM, Gheorghiade M, Greenberg BH, O’Connor CM, Sun JL, Yancy CW, Young JB. (2007) Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. J Am Coll Cardiol 50(8):768–777. doi:10.1016/j.jacc.2007.04.064
10. Gomez-Soto FM, Romero SP, Bernal JA, Escobar MA, Puerto JL, Andrey JL, Almenara J, Gomez F (2011) Mortality and morbidity of newly diagnosed heart failure with preserved systolic function treated with beta-blockers: a propensity-adjusted case-control populational study. Int J Cardiol 146(1):51–55. doi:10.1016/j.ijcard.2009.06.009
11. Smith DT, Farzaneh-Far R, Ali S, Na B, Whooley MA, Schiller NB (2010) Relation of beta-blocker use with frequency of hospitalization for heart failure in patients with left ventricular diastolic dysfunction (from the Heart and Soul Study). Am J Cardiol 105(2):223–228. doi:10.1016/j.amjcard.2009.08.677
12. Yanagihara K, Kinugasa Y, Sugihara S, Hirai M, Yamada K, Ishida K, Kato M, Yamamoto K (2013) Discharge use of carvedilol is associated with higher survival in Japanese elderly patients with heart failure regardless of left ventricular ejection fraction. J Cardiovasc Pharmacol 62(5):485–490. doi:10.1097/FJC.0000000000000006
13. Patel K, Fonarow GC, Ekundayo OJ, Aban IB, Kilgore ML, Love TE, Kitzman DW, Gheorghiade M, Allman RM, Ahmed A (2014) Beta-blockers in older patients with heart failure and preserved ejection fraction: class, dosage, and outcomes. Int J Cardiol 173(3):393–401. doi:10.1016/j.ijcard.2014.03.005
14. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17(1):1–12
15. Harris RP, Helfand M, Woolf SH, Lohr KN, Mulrow CD, Teutsch SM, Atkins D. (2001) Current methods of the US Preventive Services Task Force: a review of the process. Am J Prev Med 20(3 Suppl):21–35
16. Rienstra M, Damman K, Mulder BA, Van Gelder IC, McMurray JJ, Van Veldhuisen DJ (2013) Beta-blockers and outcome in heart failure and atrial fibrillation: a meta-analysis. JACC Heart Fail 1(1):21–28. doi:10.1016/j.jchf.2012.09.002
17. Spruance SL, Reid JE, Grace M, Samore M (2004) Hazard ratio in clinical trials. Antimicrob Agents Chemother 48(8):2787–2792. doi:10.1128/AAC.48.8.2787-2792.2004
18. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7(3):177–188
19. Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21(11):1539–1558. doi:10.1002/sim.1186
20. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315(7109):629–634
21. van Veldhuisen DJ, Cohen-Solal A, Bohm M, Anker SD, Babalis D, Roughton M, Coats AJ, Poole-Wilson PA, Flather MD, Investigators S (2009) Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: data From SENIORS (Study of effects of nebivolol intervention on outcomes and rehospitalization in seniors with heart failure). J Am Coll Cardiol 53(23):2150–2158. doi:10.1016/j.jacc.2009.02.046
22. Yamamoto K, Origasa H, Hori M, Investigators JD (2013) Effects of carvedilol on heart failure with preserved ejection fraction: the Japanese diastolic heart failure study (J-DHF). Eur J Heart Fail 15(1):110–118. doi:10.1093/eurjhf/hfs141
23. Fukuta H, Sane DC, Brucks S, Little WC (2005) Statin therapy may be associated with lower mortality in patients with diastolic heart failure: a preliminary report. Circulation 112(3):357–363. doi:10.1161/CIRCULATIONAHA.104.519876
24. Grigorian Shamagian L, Roman AV, Ramos PM, Veloso PR, Bandin Dieguez MA, Gonzalez-Juanatey JR (2006) Angiotensin-converting enzyme inhibitors prescription is associated with longer survival among patients hospitalized for congestive heart failure who have preserved systolic function: a long-term follow-up study. J Card Fail 12(2):128–133. doi:10.1016/j.cardfail.2005.09.001
25. Chan JD, Rea TD, Smith NL, Siscovick D, Heckbert SR, Lumley T, Chaves P, Furberg CD, Kuller L, Psaty BM (2005) Association of beta-blocker use with mortality among patients with congestive heart failure in the Cardiovascular Health Study (CHS). Am Heart J 150(3):464–470. doi:10.1016/j.ahj.2004.12.022
26. Dobre D, van Veldhuisen DJ, DeJongste MJ, Lucas C, Cleuren G, Sanderman R, Ranchor AV, Haaijer-Ruskamp FM (2007) Prescription of beta-blockers in patients with advanced heart failure and preserved left ventricular ejection fraction. Clinical implications and survival. Eur J Heart Fail 9(3):280–286. doi:10.1016/j.ejheart.2006.07.008
27. Shah R, Wang Y, Foody JM (2008) Effect of statins, angiotensin-converting enzyme inhibitors, and beta blockers on survival in patients > or = 65 years of age with heart failure and preserved left ventricular systolic function. Am J Cardiol 101(2):217–222. doi:10.1016/j.amjcard.2007.08.050
28. Hernandez AF, Hammill BG, O’Connor CM, Schulman KA, Curtis LH, Fonarow GC (2009) Clinical effectiveness of beta-blockers in heart failure: findings from the OPTIMIZE-HF (organized program to initiate lifesaving treatment in hospitalized patients with heart failure) registry. J Am Coll Cardiol 53(2):184–192. doi:10.1016/j.jacc.2008.09.031
29. Tehrani F, Phan A, Chien CV, Morrissey RP, Rafique AM, Schwarz ER (2009) Value of medical therapy in patients >80 years of age with heart failure and preserved ejection fraction. Am J Cardiol 103(6):829–833. doi:10.1016/j.amjcard.2008.11.047
30. El-Refai M, Peterson EL, Wells K, Swadia T, Sabbah HN, Spertus JA, Williams LK, Lanfear DE (2013) Comparison of beta-blocker effectiveness in heart failure patients with preserved ejection fraction versus those with reduced ejection fraction. J Card Fail 19(2):73–79. doi:10.1016/j.cardfail.2012.11.011
31. Nevzorov R, Porath A, Henkin Y, Kobal SL, Jotkowitz A, Novack V (2012) Effect of beta blocker therapy on survival of patients with heart failure and preserved systolic function following hospitalization with acute decompensated heart failure. Eur J Intern Med 23(4):374–378. doi:10.1016/j.ejim.2012.01.011
32. Triposkiadis F, Karayannis G, Giamouzis G, Skoularigis J, Louridas G, Butler J (2009) The sympathetic nervous system in heart failure physiology, pathophysiology, and clinical implications. J Am Coll Cardiol 54(19):1747–1762. doi:10.1016/j.jacc.2009.05.015
33. Little WC, Brucks S (2005) Therapy for diastolic heart failure. Prog Cardiovasc Dis 47(6):380–388. doi:10.1016/j.pcad.2005.02.004
34. Borlaug BA, Melenovsky V, Russell SD, Kessler K, Pacak K, Becker LC, Kass DA (2006) Impaired chronotropic and vasodilator reserves limit exercise capacity in patients with heart failure and a preserved ejection fraction. Circulation 114(20):2138–2147. doi:10.1161/CIRCULATIONAHA.106.632745
35. Conraads VM, Metra M, Kamp O, De Keulenaer GW, Pieske B, Zamorano J, Vardas PE, Bohm M, Dei Cas L (2012) Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity, and left ventricular function of patients with diastolic dysfunction: results of the ELANDD study. Eur J Heart Fail 14(2):219–225. doi:10.1093/eurjhf/hfr161
36. Ghio S, Magrini G, Serio A, Klersy C, Fucili A, Ronaszeki A, Karpati P, Mordenti G, Capriati A, Poole-Wilson PA, Tavazzi L (2006) Effects of nebivolol in elderly heart failure patients with or without systolic left ventricular dysfunction: results of the SENIORS echocardiographic substudy. Eur Heart J 27(5):562–568. doi:10.1093/eurheartj/ehi735
37. Bergstrom A, Andersson B, Edner M, Nylander E, Persson H, Dahlstrom U (2004) Effect of carvedilol on diastolic function in patients with diastolic heart failure and preserved systolic function. Results of the Swedish Doppler-echocardiographic study (SWEDIC). Eur J Heart Fail 6(4):453–461. doi:10.1016/j.ejheart.2004.02.003
38. Writing Committee M, Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL (2013) ACCF/AHA guideline for the management of heart failure: a report of the American college of cardiology foundation/American heart association task force on practice guidelines. Circulation 128(16):e240–e327. doi:10.1161/CIR.0b013e31829e8776
39. Wiysonge CS, Bradley HA, Volmink J, Mayosi BM, Mbewu A, Opie LH (2012) Beta-blockers for hypertension. Cochrane Database of Sys Rev 11:CD002003. doi:10.1002/14651858.CD002003.pub4
40. Bangalore S, Sawhney S, Messerli FH (2008) Relation of beta-blocker-induced heart rate lowering and cardioprotection in hypertension. J Am Coll Cardiol 52(18):1482–1489. doi:10.1016/j.jacc.2008.06.048
41. Bangalore S, Parkar S, Grossman E, Messerli FH (2007) A meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus. Am J Cardiol 100(8):1254–1262. doi:10.1016/j.amjcard.2007.05.057
42. Hawkins NM, Petrie MC, Macdonald MR, Jhund PS, Fabbri LM, Wikstrand J, McMurray JJ (2011) Heart failure and chronic obstructive pulmonary disease the quandary of Beta-blockers and Beta-agonists. J Am Coll Cardiol 57(21):2127–2138. doi:10.1016/j.jacc.2011.02.020
43. Zhou J, Shi H, Zhang J, Lu Y, Fu M, Ge J (2010) Rationale and design of the beta-blocker in heart failure with normal left ventricular ejection fraction (beta-PRESERVE) study. Eur J Heart Fail 12(2):181–185. doi:10.1093/eurjhf/hfp193